161 related articles for article (PubMed ID: 19930409)
1. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview.
Rzany B; Ascher B; Monheit G
J Eur Acad Dermatol Venereol; 2010 Jan; 24 Suppl 1():1-14. PubMed ID: 19930409
[TBL] [Abstract][Full Text] [Related]
2. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest.
Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1285-95. PubMed ID: 20569284
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
Rubin MG; Dover J; Glogau RG; Goldberg DJ; Goldman MP; Schlessinger J
J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
[TBL] [Abstract][Full Text] [Related]
4. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles.
Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1278-84. PubMed ID: 20337830
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
Monheit G; Carruthers A; Brandt F; Rand R
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
Monheit GD; Cohen JL;
J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines.
Ascher B; Zakine B; Kestemont P; Baspeyras M; Bougara A; Santini J
J Am Acad Dermatol; 2004 Aug; 51(2):223-33. PubMed ID: 15280841
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applications.
Rzany B; Fratila AA; Fischer TC; Hilton S; Pavicic T; Rothhaar A; Sattler G; Sommer B; Pickett A
J Drugs Dermatol; 2013 Jan; 12(1):80-4. PubMed ID: 23377332
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
12. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
Farahvash MR; Arad S
J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
Ascher B; Rzany BJ; Grover R
Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.
Fagien S; Cox SE; Finn JC; Werschler WP; Kowalski JW
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S2-9. PubMed ID: 17241410
[TBL] [Abstract][Full Text] [Related]
15. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients.
Rzany B; Dill-Müller D; Grablowitz D; Heckmann M; Caird D;
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S18-25. PubMed ID: 17241409
[TBL] [Abstract][Full Text] [Related]
16. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
17. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
Göbel H; Heinze A; Reichel G; Hefter H; Benecke R;
Pain; 2006 Nov; 125(1-2):82-8. PubMed ID: 16750294
[TBL] [Abstract][Full Text] [Related]
19. Eyebrow height after botulinum toxin type A to the glabella.
Carruthers A; Carruthers J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S26-31. PubMed ID: 17241411
[TBL] [Abstract][Full Text] [Related]
20. Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study.
Molina B; Grangier Y; Mole B; Ribe N; Martín Diaz L; Prager W; Paliargues F; Kerrouche N
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1382-8. PubMed ID: 25495499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
